AzTrials
AzTrials

EstheticsNCT04741607

Immediate Versus Late Placement

A study testing Implant placement (BLX implant system, Straumann, Basel, Switzerland), Ridge preservation (Bio-Oss Collagen 250 mg, Geistlich Pharma AG, Wolhusen, Switserland) and Socket seal (Mucograft Seal, Geistlich Pharma AG, Wolhusen, Switserland) in people with Esthetics, run by University Ghent at 2 sites in Belgium.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Patients in need of a single implant in the premaxilla will be invited to participate in this multicenter randomized controlled trial (RCT). Prior to surgery, a small-field low-dose cone beam computed tomography (CBCT) is taken to verify the integrity of the facial bone wall and an adequate amount of apical and… Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for
Esthetics
What is being tested?
Implant placement (BLX implant system, Straumann, Basel, Switzerland), Ridge preservation (Bio-Oss Collagen 250 mg, Geistlich Pharma AG, Wolhusen, Switserland) and Socket seal (Mucograft Seal, Geistlich Pharma AG, Wolhusen, Switserland)
Could I receive a placebo?
No, everyone receives an active treatment
How many people
60 participants
Where
2 sitesBelgium
Study dates
1 Jan 2021to 1 Jan 2028
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • at least 18 years old
  • good oral hygiene defined as full-mouth plaque score ≤ 25% (O'Leary et al. 1972)
  • presence of a single-rooted tooth in the anterior maxilla (15-25) that needs to be extracted for any reason with at least one neighboring tooth present
  • at least 3 mm bone available at the apical or palatal aspect of the alveolus to ensure primary implant stability
  • intact or nearly intact buccal bone wall at the time of extraction (max 3 mm bone missing = max 6 mm distance from free gingival margin to buccal bone crest)

Who cannot join

  • systemic diseases
  • smoking
  • untreated periodontal disease
  • untreated caries lesions

Trial locations and contacts

2 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Jan Cosyn, Professor contact

+3293324000

jan.cosyn@ugent.be

Lorenz Seyssens, Phd candidate contact

lorenz.seyssens@ugent.be

Belgium2 sites, 2 recruiting
  • Ghent University

    Ghent, Oost-Vlaanderen, 9000

    Jan Cosyn, Professor, jan.cosyn@ugent.be

    Lorenz Seyssens, Phd candidate, lorenz.seyssens@ugent.be

    Recruiting
  • UCL St Luc

    Liège

    Selena Toma

    Selena Toma

    Recruiting

Other trials in Belgium

About this study

Official title: Alveolar Ridge Preservation With Immediate or Late Implant Placement: a Multicenter Randomized Controlled Trial

Patients in need of a single implant in the premaxilla will be invited to participate in this multicenter randomized controlled trial (RCT). Prior to surgery, a small-field low-dose cone beam computed tomography (CBCT) is taken to verify the integrity of the facial bone wall and an adequate amount of apical and palatal bone dimensions. Sixty patients will be randomly allocated to the test group or control group in 6 centers. Each center receives 10 sealed envelopes (5 are internally labelled with 'delayed implant placement' and 5 with 'immediate implant placement').

For each patient a digital planning is performed in implant planning software and a tooth-supported surgical guide is fabricated prior to tooth extraction.

Read more

In the control group, alveolar ridge preservation is performed following tooth extraction. After a healing period of 4 months, a single implant is installed.

In the test group, a single implant is installed immediately after tooth extraction and ridge preservation is performed by filling the gap between the facial bone wall and the implant surface.

A provisional crown is placed at the day of implant surgery, which is replaced by a permanent one 3m later.

Six months after tooth extraction and subsequent ridge preservation, the need for soft tissue grafting is assessed on the base of predetermined criteria (primary outcome measure). Soft tissue augmentation is performed by inserting a palatal connective tissue graft (CTG) into the buccal mucosa at the implant site.

Secondary outcome measures include 3D hard and soft tissue changes as well as clinical, aesthetic, patient-reported and clinician-reported outcomes.

Read the detailed description

Patient selection Patients in need of a single implant in the premaxilla (15-25) will be included in this multicenter RCT following screening and after having received written consent.

Sample size calculation A sample size calculation using the Pearson Chi-square test was performed in SAS Power and Sample Size based on a comparison of the proportion on the need for soft tissue augmentation at 5 months following alveolar ridge preservation (ARP) between the control group (ARP + delayed implant placement 'DIP') and test group (ARP + immediate implant placement 'IIP'). The calculation was based on finding a 30% difference between these groups. With alpha set at 0.05 and a power of 0.80, the sample size calculation indicated 28 patients to be included per group. To compensate for drop-outs, 30 patients would be treated with ARP+DIP and 30 would be treated with ARP+IIP.

Clinicians and centers, randomization, allocation concealment and blinding Six experienced clinicians will treat at least 10 patients each. Five clinicians are staff members of the Department of Periodontology and Oral Implantology at UGent - UZ Gent, who also work part-time in different private practices. The final clinician is a professor at the Saint-Luc University Hospital (UCL). The digital workflow, the implant placement protocol, the application of a connective tissue graft (CTG) at 6 months following ARP and the restorative protocol will be thoroughly discussed among the 6 clinicians in a training session before the start of the trial.

During the training session each clinician will receive 5 sealed envelopes internally coded as 'Delayed implant placement' and another 5 as 'immediate implant placement'. Just prior to surgery, a sealed envelope will be randomly selected and opened to reveal the treatment to be conducted. The measuring investigator will not be involved in the treatment of any of the patients and will be blinded to allow unbiased registrations.

Pre-operative digital planning for fabrication of surgical guide A digital workflow will be adopted for every patient for fabrication of a surgical guide prior to tooth extraction. This requires 3D digital implant planning in designated software on the basis of a pre-op low-dose small-field Cone-Beam CT and intra-oral scan. Note that surgical guides for patients in the ARP+DIP group will also be fabricated following patient selection, even though they are only to be used 4 months later.

Control group: ARP+DIP Patients start to take systemic antibiotics (Amoxicilline 1g) and anti-inflammatory medication (Ibuprofen 600 mg) 1h pre-operatively. Following local anesthesia (Septanest special, Septodont, Saint Maur des Fossés, France) and oral disinfection (Corsodyl mouth rinse, GSK, Wavre, Belgium), the failing tooth is extracted without raising a flap. Following socket debridement and rinsing, collagen-enriched DBBM (Bio-Oss Collagen 250 mg, Geistlich Pharma AG, Wolhusen, Switserland) is applied up to the level of the palatal bone crest and slightly condensed. The occlusal aspect is closed with a collagen matrix (Mucograft Seal, Geistlich Pharma AG, Wolhusen, Switserland), which is fixed with single sutures (Seralon 6/0, Serag Weissner, Naila, Germany) to the soft tissues. Post-op instructions include the intake of systemic antibiotics during 4 days (Amoxicilline 1g, two times a day), anti-inflammatory medication as deemed necessary by the patient and oral disinfection twice a day during 1 week. Then, sutures are removed. A removable partial denture as used as provisional tooth replacement when considered needed.

At 4 months, a mucoperiosteal flap is raised, the surgical guide is applied, and the implant is installed according to manufacturer's prescriptions. Then, an implant impression is taken for fabrication of a provisional crown. Prior to wound closure with vertical mattrass sutures (Seralon 6/0, Serag Weissner, Naila, Germany), an appropriate healing abutment is installed. This healing abutment is replaced by the provisional crown two days later.

At 6 months, the need for soft tissue augmentation is assessed by the 5 clinicians who have not been clinically involved. The treating clinician is excluded since he/she cannot be blinded for the treatment group. The need for soft tissue augmentation is assessed on the basis of screenshots from the pre-op CBCT with lip retractors enabling to evaluate buccal bone and soft tissue thickness. Pre-op clinical pictures, clinical pictures at 6 months with the provisional crown in situ and the STL file at 6 months are also offered to the panel in order to assess the loss of buccal convexity.

Soft tissue augmentation is required necessary when at least one of the following criteria are met: thin gingival biotype as defined as < 1mm midfacial soft tissue thickness as assessed on pre-op CBCT with lip retractors, thin buccal bone wall as defined as < 0.5mm as assessed on pre-op CBCT, loss of ideal buccal convexity at 6 months following ARP as assessed on the basis of clinical pictures and STL. Each clinician makes a decision on the need for soft tissue augmentation for 50 out of 60 cases independent from the other clinicians. Soft tissue augmentation is offered to the patient when the majority of the panel is in favor of it.

Soft tissue augmentation is performed using a CTG harvested from the lateral palate using the single incision technique. At the recipient site, a pouch is made in the buccal mucosa and an appropriately sized CTG is pulled in. The CTG is secured into the buccal mucosa with multiple single sutures (Seralon 6/0, Serag Weissner, Naila, Germany) and the provisional crown is re-installed. Sutures are removed after 1 week. The provisional crown is replaced by a permanent crown 3 months later.

Test group: ARP+IIP Patients start to take systemic antibiotics (Amoxicilline 1g) and anti-inflammatory medication (Ibuprofen 600 mg) 1h pre-operatively. Following local anesthesia (Septanest special, Septodont, Saint Maur des Fossés, France) and oral disinfection (Corsodyl mouth rinse, GSK, Wavre, Belgium), the failing tooth is extracted without raising a flap. Following socket debridement and rinsing, the surgical guide is applied, and the implant is installed according to manufacturer's prescriptions. Then, an implant impression is taken for fabrication of a provisional crown. Finally, the gap is filled with collagen-enriched DBBM (Bio-Oss Collagen 250 mg, Geistlich Pharma AG, Wolhusen, Switserland), which is applied up to the level of the free mucosal margin, and an appropriate healing abutment is installed. This healing abutment is replaced by the provisional crown two days later.

At 6 months, the need for soft tissue augmentation is assessed by the 5 clinicians who have not been clinically involved. The treating clinician is excluded since he/she cannot be blinded for the treatment group. The need for soft tissue augmentation is assessed on the basis of screenshots from the pre-op CBCT with lip retractors enabling to evaluate buccal bone and soft tissue thickness. Pre-op clinical pictures, clinical pictures at 6 months with the provisional crown in situ and the STL file at 6 months are also offered to the panel in order to assess the loss of buccal convexity. Each clinician makes a decision on the need for soft tissue augmentation for 50 out of 60 cases independent from the other clinicians. Soft tissue augmentation is offered to the patient when the majority of the panel is in favor of it.

Soft tissue augmentation is performed using a CTG harvested from the lateral palate using the single incision technique. At the recipient site, a pouch is made in the buccal mucosa and an appropriately sized CTG is pulled in. The CTG is secured into the buccal mucosa with multiple single sutures (Seralon 6/0, Serag Weissner, Naila, Germany) and the provisional crown is re-installed. Sutures are removed after 1 week. The provisional crown is replaced by a permanent crown 3 months later.

Conditions
Esthetics
Being tested
Implant placement (BLX implant system, Straumann, Basel, Switzerland), Ridge preservation (Bio-Oss Collagen 250 mg, Geistlich Pharma AG, Wolhusen, Switserland), Socket seal (Mucograft Seal, Geistlich Pharma AG, Wolhusen, Switserland)
Keywords
connective tissue graft, dental implant, single tooth, immediate, ridge preservation

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Implant placement (BLX implant system, Straumann, Basel, Switzerland)Device

    Implants are placed after a healing period of 4 months (delayed implant placement, control group) or immediately after tooth extraction and ridge preservation (immediate implant placement, test group).

  • Ridge preservation (Bio-Oss Collagen 250 mg, Geistlich Pharma AG, Wolhusen, Switserland)Procedure or surgery

    Ridge preservation is performed by inserting a collagen-enriched DBBM (Bio-Oss Collagen 250 mg, Geistlich Pharma AG, Wolhusen, Switserland) in the empty extraction socket (delayed implant placement, control group) or by filling the gap between the implant and buccal bone wall (immediate implant placement, test group).

  • Socket seal (Mucograft Seal, Geistlich Pharma AG, Wolhusen, Switserland)Procedure or surgery

    The occlusal aspect of the grafted socket in the delayed implant placement/control group is closed with a collagen matrix.

Study groups in NCT04741607
Study groupRoleWhat they receive
Control groupActive comparatorDelayed implant placement
Receives: Device: Implant placement (BLX implant system, Straumann, Basel, Switzerland); Procedure: Ridge preservation (Bio-Oss Collagen 250 mg, Geistlich Pharma AG, Wolhusen, Switserland); Procedure: Socket seal (Mucograft Seal, Geistlich Pharma AG, Wolhusen, Switserland)
Test groupExperimentalImmediate implant placement
Receives: Device: Implant placement (BLX implant system, Straumann, Basel, Switzerland); Procedure: Ridge preservation (Bio-Oss Collagen 250 mg, Geistlich Pharma AG, Wolhusen, Switserland)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Need for soft tissue augmentation (true or false) as judged by a panel of clinicians

    The need for soft tissue augmentation is assessed by the 5 clinicians who have not been clinically involved. The treating clinician is excluded since he/she cannot be blinded for the treatment group. The need for soft tissue augmentation is assessed on the basis of clinical pictures, a CBCT image and STL file.

    Measured: 6 months

Secondary outcomes (15)
  1. Clinician-reported outcome measures

    Ease of implant placement (Visual Analogue Scale). Minimum value = 0 (Very easy) Maximum value = 10 (Very difficult)

    Measured: per-op

  2. Changes in buccal soft tissue profile

    Volumetric analysis with designated software on the basis of IOS (mm). Change in buccal soft tissue profile and the initial buccal soft tissue profile will be aggregated to calculate relative change in buccal soft tissue profile (=absolute change / initial buccal soft tissue profile, percent)

    Measured: pre-op, 6 months, 1 year, 3 years, 5 years

  3. Vertical change in midfacial soft tissue level

    Analysed with designated software on the basis of IOS (mm)

    Measured: pre-op, 6 months, 1 year, 3 years, 5 years

  4. Change in width of the alveolar process

    Horizontal measurements with designated software on the basis of CBCT scans (mm)

    Measured: pre-op, 1 year, 5 year

  5. Change in height of the alveolar process

    vertical measurements with designated software on the basis of CBCT scans (mm)

    Measured: pre-op, 1 year, 5 year

  6. Change in buccal bone thickness

    Horizontal measurements with designated software on the basis of CBCT scans (mm)

    Measured: pre-op, 1 year, 5 year

  7. Implant survival

    presence of the implant

    Measured: 6 months, 9 months, 1 year, 3 years, 5 years

  8. Complication

    Any complication

    Measured: Up to 5 years

  9. Changes in radiographic outcomes

    marginal peri-implant bone level change as assessed by intra-oral radiography (mm)

    Measured: implant placement, 1 year, 3 years, 5 years

  10. Aesthetic outcome as assessed by care providers

    Pink Aesthetic Score (0-14) = assessment of 7 different parameters (Mesial papilla, distal papilla, tissue contour, gingival level, alveolar process, coloring, texture) which are all rated 0 (worst) - 2 (best)

    Measured: pre-op, 1 year, 3 years, 5 years

  11. Aesthetic outcome as assessed by patients

    Patients aesthetic satisfaction (Visual Analogue Scale) Minimum value = 0 (Very unsatisfied) Maximum value = 10 (Very satisfied)

    Measured: pre-op, 1 year, 3 years, 5 years

  12. Keratinized mucosa width

    Vertical measurement performed with a periodontal probe (mm)

    Measured: pre-op, 1 year, 3 years, 5 years

  13. Probing pocket depth

    Probing depth measured with a periodontal probe (mm)

    Measured: pre-op, 1 year, 3 years, 5 years

  14. Bleeding on probing

    Bleeding on probing was registered 15 seconds following pocket probing at four sites per implant (mesial, distal, buccal, palatal) using a dichotomous score (0: no bleeding; 1: bleeding). These values were averaged and expressed as a percentage on implant level

    Measured: pre-op, 1 year, 3 years, 5 years

  15. Plaque

    Plaque was recorded at four sites per implant (mesial, distal, buccal, palatal) using a dichotomous score (0: no visible plaque at the soft tissue margin; 1: visible plaque at the soft tissue margin). These values were averaged and expressed as a percentage on implant level.

    Measured: pre-op, 1 year, 3 years, 5 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted5 Feb 2021
  2. Study start1 Jan 2021
  3. Primary completion1 Jan 2028 (estimated)
  4. Study completion1 Jan 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
Multicenter randomized controlled study with 2 treatment arms (control: delayed implant placement; test: immediate implant placement) and 6 centers
Masking
Double blind
Who is masked
Investigator, Outcomes assessor
Enrolment
60 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04741607
Sponsor's protocol ID
BC-08574
Status last verified
Feb 2024
First submitted
17 Oct 2020
Last updated
2 Feb 2024
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Avila-Ortiz G, Elangovan S, Kramer KW, Blanchette D, Dawson DV. Effect of alveolar ridge preservation after tooth extraction: a systematic review and meta-analysis. J Dent Res. 2014 Oct;93(10):950-8. doi: 10.1177/0022034514541127. Epub 2014 Jun 25.

    PubMed 24966231
  • Bittner N, Schulze-Spate U, Silva C, Da Silva JD, Kim DM, Tarnow D, Gil MS, Ishikawa-Nagai S. Changes of the alveolar ridge dimension and gingival recession associated with implant position and tissue phenotype with immediate implant placement: A randomised controlled clinical trial. Int J Oral Implantol (Berl). 2019;12(4):469-480.

    PubMed 31781700
  • Cosyn J, De Bruyn H, Cleymaet R. Soft tissue preservation and pink aesthetics around single immediate implant restorations: a 1-year prospective study. Clin Implant Dent Relat Res. 2013 Dec;15(6):847-57. doi: 10.1111/j.1708-8208.2012.00448.x. Epub 2012 Feb 29.

    PubMed 22376232
  • Cosyn J, Eghbali A, Hermans A, Vervaeke S, De Bruyn H, Cleymaet R. A 5-year prospective study on single immediate implants in the aesthetic zone. J Clin Periodontol. 2016 Aug;43(8):702-9. doi: 10.1111/jcpe.12571. Epub 2016 Jun 13.

    PubMed 27120578
  • Cosyn J, Pollaris L, Van der Linden F, De Bruyn H. Minimally Invasive Single Implant Treatment (M.I.S.I.T.) based on ridge preservation and contour augmentation in patients with a high aesthetic risk profile: one-year results. J Clin Periodontol. 2015 Apr;42(4):398-405. doi: 10.1111/jcpe.12384. Epub 2015 Mar 31.

    PubMed 25728590
  • Kan JY, Rungcharassaeng K, Lozada JL, Zimmerman G. Facial gingival tissue stability following immediate placement and provisionalization of maxillary anterior single implants: a 2- to 8-year follow-up. Int J Oral Maxillofac Implants. 2011 Jan-Feb;26(1):179-87.

    PubMed 21365054
  • Migliorati M, Amorfini L, Signori A, Biavati AS, Benedicenti S. Clinical and Aesthetic Outcome with Post-Extractive Implants with or without Soft Tissue Augmentation: A 2-Year Randomized Clinical Trial. Clin Implant Dent Relat Res. 2015 Oct;17(5):983-95. doi: 10.1111/cid.12194. Epub 2013 Dec 27.

    PubMed 24373419
  • Sanz M, Lindhe J, Alcaraz J, Sanz-Sanchez I, Cecchinato D. The effect of placing a bone replacement graft in the gap at immediately placed implants: a randomized clinical trial. Clin Oral Implants Res. 2017 Aug;28(8):902-910. doi: 10.1111/clr.12896. Epub 2016 Jun 7.

    PubMed 27273298
  • Seyssens L, Eghbali A, Cosyn J. A 10-year prospective study on single immediate implants. J Clin Periodontol. 2020 Oct;47(10):1248-1258. doi: 10.1111/jcpe.13352. Epub 2020 Sep 2.

    PubMed 32748983
  • Yoshino S, Kan JY, Rungcharassaeng K, Roe P, Lozada JL. Effects of connective tissue grafting on the facial gingival level following single immediate implant placement and provisionalization in the esthetic zone: a 1-year randomized controlled prospective study. Int J Oral Maxillofac Implants. 2014 Mar-Apr;29(2):432-40. doi: 10.11607/jomi.3379.

    PubMed 24683571
  • Zuiderveld EG, Meijer HJA, den Hartog L, Vissink A, Raghoebar GM. Effect of connective tissue grafting on peri-implant tissue in single immediate implant sites: A RCT. J Clin Periodontol. 2018 Feb;45(2):253-264. doi: 10.1111/jcpe.12820. Epub 2017 Dec 5.

    PubMed 28941303

Questions about this trial

What is this clinical trial studying?

A study testing Implant placement (BLX implant system, Straumann, Basel, Switzerland), Ridge preservation (Bio-Oss Collagen 250 mg, Geistlich Pharma AG, Wolhusen, Switserland) and Socket seal (Mucograft Seal, Geistlich Pharma AG, Wolhusen, Switserland) in people with Esthetics, run by University Ghent at 2 sites in Belgium.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 2 Feb 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Jan Cosyn, Professor (+3293324000, jan.cosyn@ugent.be), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Need for soft tissue augmentation (true or false) as judged by a panel of clinicians (time frame: 6 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04741607, which also lists 11 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Feb 2024.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in